ZIAD SAWI: Open Payments
NPI 1194725127 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$860 in 43 payments from 8 companies in 2025. Trend: 2023 $604 · 2024 $957 · 2025 $860
Food & beverage: $860
| Company | Payments | Amount |
|---|---|---|
| Forte Bio-Pharma LLC | 14 | $320 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 14 | $230 |
| Collegium Pharmaceutical, Inc. | 5 | $103 |
| PROTEGA PHARMACEUTIALS INC | 4 | $81 |
| IBSA Pharma Inc. | 3 | $63 |
| ABBVIE INC. | 1 | $24 |
| PFIZER INC. | 1 | $23 |
| SCILEX PHARMACEUTICALS INC. | 1 | $16 |
Products named: PROLATE, RELISTOR, ROXYBOND, XTAMPZA, Tirosint, Belbuca, UBRELVY, NURTEC ODT.
Industry payments across NV — which companies pay providers there.
